NCCN Guidelines® Insights: Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2024: Featured updates to the NCCN Guidelines Guidelines
| Authors: | Daly, M. B.; Pal, T.; Maxwell, K. N.; Churpek, J.; Kohlmann, W.; AlHilli, Z.; Arun, B.; Buys, S. S.; Cheng, H.; Domchek, S. M.; Friedman, S.; Giri, V.; Goggins, M.; Hagemann, A.; Hendrix, A.; Hutton, M. L.; Karlan, B. Y.; Kassem, N.; Khan, S.; Khoury, K.; Kurian, A. W.; Laronga, C.; Mak, J. S.; Mansour, J.; McDonnell, K.; Menendez, C. S.; Merajver, S. D.; Norquist, B. S.; Offit, K.; Rash, D.; Reiser, G.; Senter-Jamieson, L.; Shannon, K. M.; Visvanathan, K.; Welborn, J.; Wick, M. J.; Wood, M.; Yurgelun, M. B.; Dwyer, M. A.; Darlow, S. D. |
| Title: | NCCN Guidelines® Insights: Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2024: Featured updates to the NCCN Guidelines |
| Abstract: | The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/ likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome. © 2023 National Comprehensive Cancer Network® (NCCN®), All rights reserved. |
| Keywords: | genetics; cancer risk; pancreas cancer; ovarian neoplasms; genetic predisposition to disease; ovary cancer; breast cancer; genetic variability; risk factors; practice guideline; breast neoplasms; brca1 protein; brca2 protein; protein p53; uvomorulin; risk factor; high risk patient; risk assessment; prostate cancer; breast tumor; ovary tumor; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; li-fraumeni syndrome; cancer epidemiology; uterus cancer; genetic predisposition; genetic screening; germ-line mutation; genetic testing; genetic counseling; germline mutation; humans; human; male; female; article; transgender; hereditary tumor syndrome; partner and localizer of brca2; lgbtqia+ people; gender nonbinary |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 21 |
| Issue: | 10 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2023-10-01 |
| Start Page: | 1001 |
| End Page: | 1010 |
| Language: | English |
| DOI: | 10.6004/jnccn.2023.0051 |
| PUBMED: | 37856201 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
